Biologics Therapy in Paediatric Rheumatology
description
Transcript of Biologics Therapy in Paediatric Rheumatology
![Page 1: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/1.jpg)
Biologics Therapy in Paediatric Rheumatology
Rheumatology study day 2014Alice Chieng
![Page 2: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/2.jpg)
• Prevalence of JIA 400:100,000 Mannere et al
• Incidence of JIA 10-:100,000 Kunamo et al
• Greater Manchester 100 new cases per year
![Page 3: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/3.jpg)
JIA Diagnosis
• History >6 weeks• <16 yrs• ≥ 1 joint with evidence of synovitis• Exclusion of infection/ vasculitis
Radiology imaging of JointsSynovial cytologyANA/RF/ HLAB27
![Page 4: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/4.jpg)
JIA Classification• Systemic• Polyarticular RF +ve
RF –ve• Oligoarticularpersistent
extended• Psoriatic arthritis• Enthesitis-related arthritis• Other arthritis
ILAR ( International League of Associations for Rheumatology 2001)
![Page 5: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/5.jpg)
Management
![Page 6: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/6.jpg)
![Page 7: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/7.jpg)
Physiotherapy
Occupational therapist
Rheum Nurse
podiatrist
Clinical Psychologist
orthopaedic
school
growthExercises
Education
Social worker
Medical treatment
Play therapist
Information
career
Transitional
Ophthalmologist
Education
Management
![Page 8: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/8.jpg)
Medical treatment
• Depends on subtypes of JIA• Intra articular steroid injections• DMARD: methotrexate/ sulphasalazine/
leflunomide• Biologics
NICE guidance Failure or intolerance to DMARD by 3 months,
Active joint disease
![Page 9: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/9.jpg)
![Page 10: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/10.jpg)
Core Set Criteria Active Joint Counts
Restricted Joint Counts
Physician Global Assessment Score
Parental VAS
CHAQ
ESR
![Page 11: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/11.jpg)
Which biologics agent should be used?
![Page 12: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/12.jpg)
Current views on pathogenesis of Inflammatory Arthritis- 1
Smolen, J.S. et al., 2007. Lancet, Published online June13
Co- Stimulatory inhibitor- abatacept
![Page 13: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/13.jpg)
Current views on pathogenesis of Inflammatory Arthritis - 2
Smolen, J.S. et al., 2007. Lancet, Published online June13
Anti TNF- EtanerceptInfliximab
Anti IL1 and IL6-AnakinraTocilizumab
Anti-CD20 rituximab
![Page 14: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/14.jpg)
Secretion of IL 1β by monocytes in inflammatory diseases in ‑SOJIA
![Page 15: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/15.jpg)
A possible positive feedback cycle contributes to perpetuation of chronic inflammation in sJIA
Anti IL1 and IL6-AnakinraTocilizumab
![Page 16: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/16.jpg)
Therapeutic Indications - UKEtanercept
(Enbrel)
Rheumatoid arthritis
Ankylosing spondylitis
Psoriatic arthritis
Plaque psoriasis
Polyarticular juvenile idiopathic arthritis
Infliximab
(Remicade)
Rheumatoid arthritis
Ankylosing spondylitis
Psoriatic arthritis
Plaque psoriasis
Crohn’s disease
Ulcerative colitis
Adalimumab
(Humira)
Rheumatoid arthritis
Ankylosing spondylitis
Psoriatic arthritis
Crohn’s disease
Psoriasis
Poly articular Juvenile Idiopathic arthritiswww.emc.medicines.org.uk
![Page 17: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/17.jpg)
Nomenclature
‒ ximab chimeric antibody
‒ zumab humanised antibody
‒ umab human antibody
‒ cept fusion protein
![Page 18: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/18.jpg)
Structure of Etanercept
Human TNF Receptors
Human Antibody
![Page 19: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/19.jpg)
sTNFR:FcActivatedmacrophage Target
cell
Signal
sTNFR
TNFTNFR
sTNFR:Fc
Etanercept - Mode of Action
![Page 20: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/20.jpg)
Etanercept - Mode of Action
![Page 21: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/21.jpg)
Etanercept
Etanercept in Children with polyarticular JRA• 0.4mg/kg twice weekly• ACR 30 pedi- 74%• 82% discontinue coticosteroids or taper below
5mg/day• Safety: 0.12 events per patient year Lovell DJ, Giannini EH et al 2006
![Page 22: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/22.jpg)
Etanercept
• German Etanercept registry- n=1300 66% for 4 years of treatment
• Dutch Registry n=146 38% complete remission
![Page 23: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/23.jpg)
Etanercept
• BNDR Biologics New Drug Registry• N=483• 69% remained on drug after 2 years• 20.7% discontinued- poor efficacy, non
compliance
![Page 24: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/24.jpg)
Etanercept- Adverse Events
• Injection site reaction 39%• URTI 35%• SAE 15% include severe infection• Malignancy and demyelination is rare • New onset uveitis and Cronhs Diseases
Tauber et al 2006, Giannini 2009, Lovell et al 2008
![Page 25: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/25.jpg)
![Page 26: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/26.jpg)
Infliximab• chimeric human–mouse monoclonal
antibody directed against TNF-α• 6 mg/kg at 0, 2 and 4 weeks • 4-8 weeks interval after• apoptosis of cells bearing TNF-α• Not licensed or FDA approved JIA• Crohns >6 yrs
![Page 27: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/27.jpg)
Infliximab
• Lovell Ruperto 2007/ 2010n=122ACR pedi 50/70- 70%/52% at wk 52Infusion reaction 32%
Discontinued 34% Only 30% continue to wk 204
![Page 28: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/28.jpg)
Infliximab
Adverse events• 91% (71/78) reported AE• 1 patient died due to JRA flare with cardiac arrest• infusion reaction 32%• SAE 21.8%
asymptomatic TB in 1 childflares of arthritis, pneumonia
![Page 29: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/29.jpg)
Adalimumab
• Human Anti TNF IgG monoclonal antibody• Dose=24mg/m₂ subcutaneous Injection 2 weekly• Lovell, Ruperto et al 2008 n=171 ACR 30/50/70 monotherapy -74/64/46% ACR 30/50/70 + mtx- 94/91/71
![Page 30: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/30.jpg)
Adalimumab
• Safety: infection 25%• Hypersensitive reaction 6%• Adalumumab antibodies 16%• ACR100 after 2 years: 40%• More effective in uveitis associated with JIA
![Page 31: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/31.jpg)
Tocilizumab
• Recombinant human interleukin 6 receptor antibody
![Page 32: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/32.jpg)
Tocilizumab
• n=56, 8mg /kg 2 wkly infusion• ACR pedi 30/50/70- 91/82/68%• CRP<50 in 2weeks in 86%• Wk 48, 98% still on medication• ACR pedi 30/50/70- 98/94/90%
Yokota et al
![Page 33: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/33.jpg)
Tocilizumab
• Tender Trial- SOJIA n= 88 ACR 30 with no fever 88% ACR70/90- 89%/65% 48% reduction in coticosteroids 33 SAE- 12 attributed by tocilizumab 12 infections- 6 by tocilizumab Ruperto et al 2012
![Page 34: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/34.jpg)
Cherish Trial for poly JIA
![Page 35: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/35.jpg)
Anakinra• Anti IL 1 receptor antagonist
• Lequerre et al 2008 in SOJIAn=20, Duration 6 monthsDose 1-2mg/kg/dayACR paed 50 in 20% AE in 4 patients with severe skin reaction, infection
![Page 36: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/36.jpg)
Anakinra
• IL-1 receptor antagonist• 1–2 mg/kg (max 100 mg daily) by SC• Rosellini et al n=80 SOJIA, poly and oligo 73% responded SOJIA, ACR 30/50- 55/30%• Anajis Trial n=24, placebo/anakinra 67% responded
![Page 37: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/37.jpg)
Rilonacept
• IL-1 R/IL1RacP/Fc fusion protein• Gianinni et al n=9 ACR 50 at 2/4 wks-55/78% sustained at 24 months 2 MAS• On going double blind placebo trial
![Page 38: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/38.jpg)
Abatacept (CTLA4-Ig)A receptor immunoglobulin fusion protein
Adapted from Kremer, J.M., 2004. Rheum Dis Clin N Am, 30, pp. 381–391
![Page 39: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/39.jpg)
Abatacept
• Phase III double blind withdraw trial in Poly JIA• 10 mg/kg IV 4 weekly, n=199• ACR 30/50/70 in 64%/50%/28% achieved• SAE: 6, one ALL, 2 flares of arthritis, joint wear,
Varicella Zoster, ovarian cyst• AE: headache and nausea
![Page 40: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/40.jpg)
Safety with anti TNF• Minor URTI most common• TB reported in infliximab and adalimumab• Demyelinating disease, uveitis, IBD rare• Drug induced lupus rare• Malignancy- 48 reported by FDA88% also received immuno-suppressiveLymphoma, leukaemia, melanoma and solid tumour
![Page 41: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/41.jpg)
Malignancies• Rheumatic conditions (20 cases in total, of which 5 are associated with infliximab, 14 with etanercept and 1 with adalimumab, and includes the conditions: JIA, 15 cases; ankylosing spondylitis, 3 cases; psoriatic
arthritis, 1 case; sarcoidosis, 1 case)
• Other conditions (28 cases in total, of which 26 are associated with infliximab, 1 with etanercept and 1 with adalimumab, and includes the conditions: Crohn disease, 21 cases; ulcerative colitis, 4 cases; in utero exposure, 2 cases; unknown, 1 case)
Hashkets 2010 Nature
![Page 42: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/42.jpg)
• Hepatosplenic T-cell lymphoma* (10 cases)• Non-Hodgkin lymphoma (7 cases)• Hodgkin lymphoma (6 cases)• Leukemia (6 cases)• Malignant melanoma (3 cases)• Thyroid cancer (3 cases)• Basal cell carcinoma, lymphoma with acute myeloid leukemia, leiomyosarcoma, nephroblastoma, renal cell carcinoma, liver cancer, metastatic hepatocellular carcinoma, malignant mastocytosis, neuroblastoma, colorectal cancer, yolk-sactumor, myelodysplasia, bladder cancer (1 case each)
Types of malignancy
![Page 43: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/43.jpg)
Long Term Safety
• British Society for Paediatric and Adolescent Rheumatology Biologic and New Drug Registry for JIA
• All children on etanercept are on the national registry
![Page 44: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/44.jpg)
Summary
• High cost with £8000 to £15,000 per year per patient
• Accessibility is variable in UK• Well tolerated • Transition to adults• Long term safety
![Page 45: Biologics Therapy in Paediatric Rheumatology](https://reader030.fdocuments.in/reader030/viewer/2022020219/568146b5550346895db3d6e0/html5/thumbnails/45.jpg)